MDMA

MDMA (3,4 Methyledioxymethamphetamine) is considered an empathogen-entactogen and stimulant. The MAPS organization is in phase 3 clinical trials of MDMA-assisted psychotherapy which has demonstrated statistically significant improvement in PTSD after just three sessions. It is also being studied in couples, eating disorders, social anxiety in autistic adults, people coping with life-threatening illnesses and in healthy controls with no specific disorder. MDMA greatly diminishes the fear response and so trauma can be faced and integrated with a new perspective.

​

We will be accepting patients for MDMA-assisted psychotherapy when it is legal and our clinical site is authorized for use of MDMA. In the meantime, please visit www.maps.org for more information or to request enrollment in a clinical trial.